From NEJM Journal Watch (5/8/20): A New First-Line Treatment Regimen for H. pylori Infection
In this industry-funded, phase III trial conducted in the U.S., 455 H. pylori-treatment–naive patients with dyspepsia and a confirmed H. pylori diagnosis were randomized to treatment with capsules containing rifabutin, amoxicillin, and omeprazole or capsules containing amoxicillin and omeprazole for 14 days. Participants took 4 capsules every 8 hours. The eradication rate in the rifabutin-based therapy group was significantly higher (84%) compared with the comparison group (58%). In patients with confirmed adherence to treatment, the eradication rates were 90% versus 65%, respectively. No H. pylori resistance to rifabutin was detected, and side effects were similar between groups.
My take: More treatment options are needed due to drug resistance. Also, “further studies are needed to compare this new triple therapy with current quadruple therapies.”
Related blog posts:
- Quadruple Therapy for Helicobacter Pylori Favored in Toronto Guidelines
- ACG Guideline for Helicobacter Pylori | gutsandgrowth
- It is Getting Harder to Treat H pylori -Here’s Why
- Helicobacter pylori –useful advice
- Understanding Resistance to Helicobacter pylori | gutsandgrowth
- Salvage Therapy and Standard Therapy for H pylori | gutsandgrowth
- High Rates of Helicobacter Pylori Resistance | gutsandgrowth
- What is evidence-based medicine for H pylori? gutsandgrowth
- H pylori –useful advice gutsandgrowth
- Twyman’s Law | gutsandgrowth
